123 related articles for article (PubMed ID: 23352458)
1. Is the HCV pipeline heading in the right direction?
Aronsohn A; Muir AJ; Swan T; Jensen D
Gastroenterology; 2013 Mar; 144(3):482-5. PubMed ID: 23352458
[No Abstract] [Full Text] [Related]
2. The successful use of telaprevir to treat hepatitis C recurrence after liver transplantation in an HIV co-infected patient.
Alkhouri N; Singh G; Carey WD; Fung JJ; Zein NN; Eghtesad B; Taege A
Transplantation; 2014 Jan; 97(2):e14-5. PubMed ID: 24434485
[No Abstract] [Full Text] [Related]
3. Prompt arrival of antivirals against hepatitis C for HIV patients.
Barreiro P; Vispo E
AIDS Rev; 2010; 12(4):242-3. PubMed ID: 21344779
[No Abstract] [Full Text] [Related]
4. Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era.
Soriano V; Labarga P; Vispo E; Fernández-Montero JV; Barreiro P
Infect Dis Clin North Am; 2012 Dec; 26(4):931-48. PubMed ID: 23083825
[TBL] [Abstract][Full Text] [Related]
5. Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient.
Rodríguez-Torres M
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1117-28. PubMed ID: 23199398
[TBL] [Abstract][Full Text] [Related]
6. Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
Bruno R; Fagiuoli S; Sacchi P
Expert Rev Anti Infect Ther; 2011 Sep; 9(9):699-701. PubMed ID: 21905777
[No Abstract] [Full Text] [Related]
7. New pharmacotherapy for hepatitis C.
Assis DN; Lim JK
Clin Pharmacol Ther; 2012 Sep; 92(3):294-305. PubMed ID: 22850602
[TBL] [Abstract][Full Text] [Related]
8. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates.
Terrault NA; McCaughan GW; Curry MP; Gane E; Fagiuoli S; Fung JYY; Agarwal K; Lilly L; Strasser SI; Brown KA; Gadano A; Kwo PY; Burra P; Samuel D; Charlton M; Pessoa MG; Berenguer M
Transplantation; 2017 May; 101(5):945-955. PubMed ID: 28437387
[No Abstract] [Full Text] [Related]
9. Viable strategies to facilitate liver transplantation for human immunodeficiency virus coinfection.
Stock PG; Fung J
Liver Transpl; 2009 Sep; 15(9):1003-6. PubMed ID: 19718639
[No Abstract] [Full Text] [Related]
10. Infections and organ transplantation: new challenges for prevention and treatment of hepatitis C virus.
Burra P; De Martin E
Transplant Proc; 2011; 43(6):2455-6. PubMed ID: 21839292
[TBL] [Abstract][Full Text] [Related]
11. Management of end-stage liver disease in HIV/hepatitis C virus co-infection.
Spengler U
Curr Opin HIV AIDS; 2011 Nov; 6(6):527-33. PubMed ID: 21918437
[TBL] [Abstract][Full Text] [Related]
12. [Hepatitis C virus-related cirrhosis: is antiviral treatment mandatory?].
Castera L; Roulot D; Trinchet JC; Beaugrand M
Gastroenterol Clin Biol; 2001 May; 25(5):509-13. PubMed ID: 11521104
[No Abstract] [Full Text] [Related]
13. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients.
Terrault NA; Berenguer M; Strasser SI; Gadano A; Lilly L; Samuel D; Kwo PY; Agarwal K; Curry MP; Fagiuoli S; Fung JYY; Gane E; Brown KA; Burra P; Charlton M; Pessoa MG; McCaughan GW
Transplantation; 2017 May; 101(5):956-967. PubMed ID: 28437388
[No Abstract] [Full Text] [Related]
14. New Indications for Harvoni.
Med Lett Drugs Ther; 2016 Jan; 58(1485):6. PubMed ID: 27099890
[No Abstract] [Full Text] [Related]
15. [Victrelis and Incivek against hepatitis C: some promising options].
Sabourin G
Perspect Infirm; 2012; 9(1):58-9. PubMed ID: 22295460
[No Abstract] [Full Text] [Related]
16. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C.
Burra P
Semin Liver Dis; 2009 Feb; 29(1):53-65. PubMed ID: 19235659
[TBL] [Abstract][Full Text] [Related]
18. New Merck and Vertex drugs raise standard of care in hepatitis C.
Sheridan C
Nat Biotechnol; 2011 Jul; 29(7):553-4. PubMed ID: 21747363
[No Abstract] [Full Text] [Related]
19. Evaluation of the possible influence of hepatitis C virus and liver fibrosis on HIV type 1 immunological and virological outcomes.
Collazos J; Cartón JA; Asensi V
HIV Med; 2011 May; 12(5):308-15. PubMed ID: 20946441
[TBL] [Abstract][Full Text] [Related]
20. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail.
Charlton M
Hepatology; 2011 Jul; 54(1):3-5. PubMed ID: 21710471
[No Abstract] [Full Text] [Related]
[Next] [New Search]
